Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.69, No.5, p.1217–1227, 2022 |
||
Title: XIST as a valuable biomarker for prognosis and clinical parameters in diverse tumors: a comprehensive meta- and bioinformatics analysis | ||
Author: Mei-Jing Zhang, Zhe Yan, Jing Qin, Tian-Hang Luo, Biao Yang | ||
Abstract: Long non-coding RNA (lncRNA) X inactivate-specific transcript (XIST) has been found dysregulated in a variety of human tumors and influenced the clinicopathologic characteristics in cancer patients. Therefore, we systematically searched relevant literature that has identified the correlation of lncRNA XIST expression and clinical outcomes of tumor patients and conducted this meta-analysis to elucidate the clinical prognostic value of long noncoding RNA XIST in human tumors. A comprehensive literature search was performed from PubMed, Web of Science, EMBASE, and Cochrane library databases up to August 1, 2019. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% Cl) were calculated to evaluate the prognosis, as well as the clinicopathological parameters of XIST, respectively. We also further validated this meta-analysis using The Cancer Genome Atlas (TCGA) dataset. Results The outcome revealed that XIST overexpression in tumor tissue was interacted to a poor overall survival (OS) (HR = 0.52, 95% CI: 0.44-0.61, p < 0.0001), disease-free survival (DFS) (HR = 0.50; 95% CI: 0.36-0.69, p < 0.0001), tumor type (digestive system malignancies, HR = 0.53; 95% CI: 0.44-0.63, p < 0.0001); nondigestive system malignancies, HR = 0.48; 95% CI: 0.34-0.67, p < 0.0001), lymph node metastasis(LNM) (OR = 0.61, 95% CI: 0.37-1.00; p = 0.048), differentiation (OR = 1.46; 95% CI 0.94-2.29; p=0.096), distant metastasis (DM) (OR=0.48, 95% CI: 0.31-0.75; p = 0.001), tumor size (OR = 0.59, 95% CI: 0.38-0.92; p = 0.019), and tumor stage (OR = 2.36; 95% CI: 1.62-3.43; p < 0.001). Conclusions XIST could have potential value in early diagnosis and result in prediction and provided a novel view for the therapeutic target in clinical application. |
||
Keywords: long non-coding RNA; XIST; meta-analysis; bioinformatics analysis; prognostic biomarker | ||
Published online: 28-Jul-2022 | ||
Year: 2022, Volume: 69, Issue: 5 | Page From: 1217, Page To: 1227 | |
doi:10.4149/neo_2022_220329N352 |
||
|
download file |
|